12 Trends in Biosimilars Development Enhancing 2026 Global Access Bridging the Gap with High Quality Biosimilar Therapeutics
In 2026, the clinical community has seen a significant shift toward the primary use of biosimilars development to manage chronic inflammatory conditions. This transition is supported by a wealth of real-world evidence confirming that these agents provide the same clinical outcomes as their originator counterparts. The strategic use of...